One extraordinary case is forcing researchers to ask a fascinating question: How much function can remain hidden inside a brain affected by advanced dementia?

At BRAINSUPREME, we start with the research.

And every once in a while, a piece of research comes along that makes you stop, reread it, and ask:

What the hell just happened here?

A case report published in Frontiers in Neuroscience in May 2026 describes an elderly woman with advanced Alzheimer’s disease who experienced a remarkable series of functional improvements after receiving a large, supervised dose of psilocybin-containing mushrooms.

She began talking. She began walking without assistance. She dressed herself and her emotional expression returned, her social engagement increased and after years of urinary incontinence, she reportedly regained continence.

It is an astonishing story.

But before anyone starts calling psilocybin a cure for Alzheimer’s, there is something extremely important to understand:

This happened to one person.

There was no placebo group. There was no randomized trial. The diagnosis had been made clinically rather than confirmed using modern Alzheimer’s biomarkers, and researchers cannot prove that psilocybin caused the improvements.

The scientists who published the case explicitly warn that their observations should not be interpreted as reversal of Alzheimer’s disease.

So this isn't a story about a miracle cure.

It may be something even more scientifically interesting.

It is a story about what might still be hiding inside the human brain.

The Case That Got Researchers Talking

The woman described in the report was in her 80s and had lived with a clinical diagnosis of Alzheimer’s disease for roughly a decade.

For approximately five years, her functioning had become severely limited.

According to the case report, she had predominantly monosyllabic speech, chronic urinary incontinence, difficulty swallowing, impaired executive function, limited mobility, little spontaneous communication, flat emotional expression, and significant dependence on caregivers for everyday activities.

In other words, this was not someone experiencing mild forgetfulness.

The researchers described what appeared to be advanced neurodegenerative disease.

Then came the intervention.

Under supervision and with consent from her legal guardian, she received 5 grams of psilocybin-containing mushrooms.

That is a very large amount of mushroom material compared with doses typically discussed in recreational contexts, and the authors themselves characterize the approach as exploratory. There is currently no established psilocybin dosing protocol for advanced dementia.

The initial experience was not uneventful.

She developed profuse sweating, suspected hyperthermia and entered what researchers described as a prolonged deep sleep-like state.

Then something unexpected happened.

Approximately 19 hours after administration, she spontaneously began engaging in autobiographical conversation for several hours.

For someone who had spent years communicating largely in single syllables, that was extraordinary.

And it didn't end there.

What Happened Over the Following Days?

Researchers documented changes across several areas of functioning.

By the day after the experience, she appeared more alert and recognized family members.

By approximately the second day, she was reportedly walking independently.

Within two to three days, she began dressing herself and showing more initiative.

Her diapers remained dry, including overnight.

During the following week, researchers observed increased eye contact, reciprocal smiling and behaviors suggesting improved contextual and working memory.

Some of these improvements persisted for weeks.

One month later, because improvements were reportedly still present, the woman underwent a second supervised session using 3 grams of psilocybin-containing mushrooms.

During that experience she was considerably more verbally expressive.

Researchers described spontaneous humor, improved facial expression, emotional reciprocity, increased agility while walking and emotionally meaningful autobiographical imagery.

Medical News Today described the case as remarkable while emphasizing exactly what the research community should emphasize:

This is a signal worth investigating.

It is not proof that psilocybin treats or reverses Alzheimer's disease.

So What Could Possibly Be Happening?

This is where the story becomes fascinating from a brain-science perspective.

For decades, our picture of advanced neurodegeneration has largely been one of progressive destruction.

Neurons deteriorate.

Synapses disappear.

Communication networks become disrupted.

Functions disappear.

And once enough deterioration occurs, we tend to assume those abilities are simply gone.

But what if some of them aren't completely gone?

What if some neural circuits become inaccessible rather than entirely destroyed?

That is one hypothesis raised by this case.

The authors suggest that residual functional capacity may sometimes remain inside a severely impaired brain and could potentially become temporarily accessible when large-scale brain networks are reorganized.

That idea has enormous implications.

Not just for psychedelic research.

For neuroscience itself.

Psilocybin and the Brain

After psilocybin enters the body, it is converted into psilocin.

Psilocin interacts strongly with serotonin receptors—particularly the 5-HT2A receptor.

Activation of this system can dramatically change the way different regions of the brain communicate.

Human neuroimaging research has shown that psilocybin can temporarily alter the integrity and segregation of established brain networks, producing a state in which communication patterns become less rigid and more globally integrated.

Put more simply:

The brain temporarily begins communicating differently.

And that may matter enormously.

Neuroplasticity: The Brain's Ability to Change

One of the most interesting areas of psychedelic research involves neuroplasticity.

Neuroplasticity refers to the brain's ability to reorganize connections, adapt to new information and modify the strength or structure of neural pathways.

Preclinical research cited by the authors suggests that serotonergic psychedelics may promote processes associated with structural and functional plasticity, including dendritic growth and synaptic remodeling.

That does not mean psilocybin regrows an Alzheimer's brain.

That's a leap the evidence absolutely does not support.

But it does create an intriguing possibility.

If surviving neural networks remain partially functional but poorly coordinated, temporarily increasing network flexibility could theoretically allow those circuits to communicate in ways they previously could not.

Medical News Today interviewed neuroscientist Dustin Hines, PhD, who offered a version of this hypothesis: some neural circuits in Alzheimer's disease might be impaired without being completely destroyed, and psychedelic-induced increases in network flexibility could potentially allow residual functions to temporarily re-emerge. He also stressed that this remains a hypothesis, not an established mechanism.

That distinction matters.

But so does the hypothesis.

The Default Mode Network: Could the Brain Be “Rebooting” Its Communication?

Another area attracting attention is the brain's default mode network, or DMN.

The DMN is a collection of interconnected brain regions associated with processes including autobiographical memory, self-referential thought and internally focused cognition.

Alzheimer's disease is associated with significant disruption of this network.

Psilocybin also happens to produce major changes in DMN organization.

Research has found that psilocybin can reduce conventional connectivity within established networks while temporarily increasing communication between regions that do not typically interact as strongly.

Medical News Today spoke with epidemiologist Tim Spector, who suggested that because both Alzheimer's disease and psilocybin affect default mode network organization, changes to this system might theoretically contribute to some of the observed effects.